x-82
Small moleculeexperimental
Clinical trial activity
14 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
11
Phase 3
1
Phase 4
0
Earliest trial started Feb 1, 2011 (NCT01296581)
Timeline
Indications
Studied for
- Adenocarcinoma · Phase 1/Phase 2
- Angiogenesis Inhibitors · Phase 2
- Carcinoma, Hepatocellular · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Renal Cell · Phase 3
- Drug Therapy · Phase 2
- Esophageal Neoplasms · Phase 1
- Eye Diseases · Phase 2
- Immunotherapy · Phase 2
- Kidney Neoplasms · Phase 1/Phase 2
- Lung Neoplasms · Phase 2
- Macular Degeneration · Phase 2
- Molecular Targeted Therapy · Phase 2
- Neoplasms · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 1/Phase 2
- Retinal Degeneration · Phase 2
- Retinal Diseases · Phase 2
- Small Cell Lung Carcinoma · Phase 2
- Stomach Neoplasms · Phase 1
- Thymoma · Phase 1/Phase 2
- Wet Macular Degeneration · Phase 2
Mechanism of action
Vascular endothelial growth factor receptor inhibitor
Platelet-derived growth factor receptor inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)N[C@H]1CCN(C(=O)N(C)C)C1- Mol. weight
- 439.49 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297587 ↗
- ChEMBLCHEMBL3545401 ↗
Also known as
- x-82
- x-82
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07165418 | Phase 3 | Sep 25, 2025 | Peking University |
| NCT07047001 | Phase 2 | Apr 24, 2025 | Sun Yat-Sen University |
| NCT06728852 | Phase 2 | Dec 1, 2024 | Sun Yat-Sen University |
| NCT06523049 | Phase 2 | Aug 31, 2024 | Sichuan University |
| NCT06577961 | Phase 1/Phase 2 (Phase 2) | Aug 31, 2024 | Chinese Academy of Medical Sciences |
| NCT06406673 | Phase 2 | Oct 16, 2023 | Henan Medical University |
| NCT04373369 | Phase 2 | Jul 1, 2020 | Washington University in St. Louis, Xcovery |
| NCT03511222 | Phase 1 | Sep 11, 2018 | Washington University in St. Louis, Xcovery |
| NCT03583086 | Phase 1/Phase 2 (Phase 2) | Jul 10, 2018 | Bristol-Myers Squibb, Vanderbilt University, Xcovery |
| NCT02348359 | Phase 2 | Mar 1, 2015 | Tyrogenex |
| NCT02146222 | Phase 1 | Sep 1, 2014 | National Cancer Institute (NCI), Tyrogenex, University of Wisconsin |
| NCT01784861 | Phase 1/Phase 2 (Phase 2) | May 3, 2013 | Washington University in St. Louis |
| NCT01674569 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2012 | Tyrogenex |
| NCT01296581 | Phase 1 | Feb 1, 2011 | Tyrogenex |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Tyrogenex | For profit | 4 | 3 | 2 | 2011 |
| Washington University in St. Louis | Academic/Hospital | 3 | 3 | 2 | 2013 |
| Xcovery | For profit | 3 | 0 | 2 | 2018 |
| Sun Yat-Sen University | Academic/Hospital | 2 | 2 | 1 | 2024 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2018 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Henan Medical University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2014 |
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Sichuan University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Wisconsin | Academic/Hospital | 1 | 1 | 1 | 2014 |
| Vanderbilt University | Academic/Hospital | 1 | 1 | 1 | 2018 |
12 organizations
Page 1 / 1